R. Stupp, W. P. Mason, M. J. Van-den-bent, M. Weller, B. Fisher et al., Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma, N Engl J Med, vol.352, pp.987-996, 2005.

J. P. Thakkar, T. A. Dolecek, C. Horbinski, Q. T. Ostrom, D. D. Lightner et al., Epidemiologic and molecular prognostic review of glioblastoma, Cancer Epidemiol Biomarkers Prev, vol.23, pp.1985-1996, 2014.

E. G. Van-meir, C. G. Hadjipanayis, A. D. Norden, H. K. Shu, P. Y. Wen et al., Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma, CA Cancer J Clin, vol.60, pp.166-193, 2010.

A. Bellahcene, V. Castronovo, K. U. Ogbureke, L. W. Fisher, and N. S. Fedarko, Small integrin-binding ligand N-linked glycoproteins (SIBLINGs): multifunctional proteins in cancer, Nature reviews Cancer, vol.8, pp.212-226, 2008.

D. Coppola, M. Szabo, D. Boulware, P. Muraca, M. Alsarraj et al., Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies, Clin Cancer Res, vol.10, pp.184-190, 2004.

V. V. Hira, K. J. Ploegmakers, F. Grevers, U. Verbovsek, C. Silvestre-roig et al., Van Noorden CJ. CD133+ and Nestin+ Glioma Stem-Like Cells Reside Around CD31+ Arterioles in Niches that Express SDF-1alpha, CXCR4, Osteopontin and Cathepsin K, J Histochem Cytochem, vol.63, pp.481-493, 2015.

B. S. Sun, Q. Z. Dong, Q. H. Ye, H. J. Sun, H. L. Jia et al., Lentiviralmediated miRNA against osteopontin suppresses tumor growth and metastasis of human hepatocellular carcinoma, Hepatology, vol.48, pp.1834-1842, 2008.

L. R. Rodrigues, J. A. Teixeira, F. L. Schmitt, M. Paulsson, and H. Lindmark-mansson, The role of osteopontin in tumor progression and metastasis in breast cancer, Cancer Epidemiol Biomarkers Prev, vol.16, pp.1087-1097, 2007.

I. S. Hsieh, W. H. Huang, H. C. Liou, W. J. Chuang, R. S. Yang et al., Upregulation of drug transporter expression by osteopontin in prostate cancer cells, Mol Pharmacol, vol.83, pp.968-977, 2013.

Y. Saitoh, J. Kuratsu, H. Takeshima, S. Yamamoto, and Y. Ushio, Expression of osteopontin in human glioma. Its correlation with the malignancy, Lab Invest, vol.72, pp.55-63, 1995.

P. Sreekanthreddy, H. Srinivasan, D. M. Kumar, M. B. Nijaguna, S. Sridevi et al., Identification of potential serum biomarkers of glioblastoma: serum osteopontin levels correlate with poor prognosis, Cancer Epidemiol Biomarkers Prev, vol.19, pp.1409-1422, 2010.

V. Lamour, L. Mercier, M. Lefranc, F. Hagedorn, M. Javerzat et al., Selective osteopontin knockdown exerts anti-tumoral activity in a human glioblastoma model, Int J Cancer, vol.126, pp.1797-1805, 2010.

V. Lamour, A. Henry, J. Kroonen, M. J. Nokin, Z. Von-marschall et al., Targeting osteopontin suppresses glioblastoma stem-like cell character and tumorigenicity in vivo, Int J Cancer, vol.137, pp.1047-1057, 2015.

S. H. Chang, A. Minai-tehrani, J. Y. Shin, S. Park, J. E. Kim et al., Beclin1-induced autophagy abrogates radioresistance of lung cancer cells by suppressing osteopontin, J Radiat Res, vol.53, pp.422-432, 2012.

A. Hahnel, H. Wichmann, M. Kappler, M. Kotzsch, D. Vordermark et al., Effects of osteopontin inhibition on radiosensitivity of MDA-MB-231 breast cancer cells, Radiat Oncol, vol.5, p.82, 2010.

A. K. Rud, K. Boye, M. Oijordsbakken, M. Lund-iversen, A. R. Halvorsen et al., Osteopontin is a prognostic biomarker in non-small cell lung cancer, BMC Cancer, vol.13, p.540, 2013.

S. R. Rittling and A. F. Chambers, Role of osteopontin in tumour progression, Br J Cancer, vol.90, pp.1877-1881, 2004.

V. H. Bramwell, G. S. Doig, A. B. Tuck, S. M. Wilson, K. S. Tonkin et al., Serial plasma osteopontin levels have prognostic value in metastatic breast cancer, Clin Cancer Res, vol.12, pp.3337-3343, 2006.

R. Liersch, J. Gerss, C. Schliemann, M. Bayer, C. Schwoppe et al., Osteopontin is a prognostic factor for survival of acute myeloid leukemia patients, Blood, vol.119, pp.5215-5220, 2012.

G. F. Weber, G. S. Lett, and N. C. Haubein, Osteopontin is a marker for cancer aggressiveness and patient survival, Br J Cancer, vol.103, pp.861-869, 2010.

B. Mukherjee, B. Mcellin, C. V. Camacho, N. Tomimatsu, S. Sirasanagandala et al., EGFRvIII and DNA double-strand break repair: a molecular mechanism for radioresistance in glioblastoma, Cancer Res, vol.69, pp.4252-4259, 2009.

M. Nitta, D. Kozono, R. Kennedy, J. Stommel, K. Ng et al., Targeting EGFR induced oxidative stress by PARP1 inhibition in glioblastoma therapy, PLoS One, vol.5, p.10767, 2010.

G. Wohlleben, A. Scherzad, A. Guttler, D. Vordermark, S. Kuger et al., Influence of hypoxia and irradiation on osteopontin expression in head and neck cancer and glioblastoma cell lines, Radiat Oncol, vol.10, p.167, 2015.

A. Guttler, M. Giebler, P. Cuno, H. Wichmann, J. Kessler et al., Osteopontin and splice variant expression level in human malignant glioma: radiobiologic effects and prognosis after radiotherapy, Radiother Oncol, vol.108, pp.535-540, 2013.

D. T. Denhardt and A. F. Chambers, Overcoming obstacles to metastasis--defenses against host defenses: osteopontin (OPN) as a shield against attack by cytotoxic host cells, J Cell Biochem, vol.56, pp.48-51, 1994.

D. Friedmann-morvinski, V. Bhargava, S. Gupta, I. M. Verma, and S. Subramaniam, Identification of therapeutic targets for glioblastoma by network analysis, Oncogene, vol.35, pp.608-620, 2016.

N. Goffart, J. Kroonen, and B. Rogister, Glioblastoma-initiating cells: relationship with neural stem cells and the microenvironment, Cancers (Basel), vol.5, pp.1049-1071, 2013.

S. Bao, Q. Wu, R. E. Mclendon, Y. Hao, Q. Shi et al., Glioma stem cells promote radioresistance by preferential activation of the DNA damage response, Nature, vol.444, pp.756-760, 2006.

L. Biddlestone-thorpe, M. Sajjad, E. Rosenberg, J. M. Beckta, N. C. Valerie et al., ATM kinase inhibition preferentially sensitizes p53-mutant glioma to ionizing radiation, Clin Cancer Res, vol.19, pp.3189-3200, 2013.

G. Del-alcazar, C. R. Hardebeck, M. C. Mukherjee, B. Tomimatsu, N. Gao et al., Inhibition of DNA double-strand break repair by the dual PI3K/mTOR inhibitor NVP-BEZ235 as a strategy for radiosensitization of glioblastoma, Clin Cancer Res, vol.20, pp.1235-1248, 2014.

H. K. Gan, A. N. Cvrljevic, and T. G. Johns, The epidermal growth factor receptor variant III (EGFRvIII): where wild things are altered, FEBS J, vol.280, pp.5350-5370, 2013.

S. E. Golding, R. N. Morgan, B. R. Adams, A. J. Hawkins, L. F. Povirk et al., Pro-survival AKT and ERK signaling from EGFR and mutant EGFRvIII enhances DNA double-strand break repair in human glioma cells, Cancer Biol Ther, vol.8, pp.730-738, 2009.

J. Li and D. F. Stern, Regulation of CHK2 by DNA-dependent protein kinase, J Biol Chem, vol.280, pp.12041-12050, 2005.

A. C. Begg, F. A. Stewart, and C. Vens, Strategies to improve radiotherapy with targeted drugs, Nat Rev Cancer, vol.11, pp.239-253, 2011.

G. Lammering, Anti-epidermal growth factor receptor strategies to enhance radiation action, Curr Med Chem Anticancer Agents, vol.3, pp.327-333, 2003.

Y. Kim, Y. S. Lee, J. Choe, H. Lee, Y. M. Kim et al., CD44-epidermal growth factor receptor interaction mediates hyaluronic acid-promoted cell motility by activating protein kinase C signaling involving Akt, Rac1, Phox, reactive www.impactjournals.com/oncotarget oxygen species, focal adhesion kinase, and MMP-2, J Biol Chem, vol.283, pp.22513-22528, 2008.

A. Perez, D. M. Neskey, J. Wen, L. Pereira, E. P. Reategui et al., CD44 interacts with EGFR and promotes head and neck squamous cell carcinoma initiation and progression, Oral Oncol, vol.49, pp.306-313, 2013.

A. Pietras, A. M. Katz, E. J. Ekstrom, B. Wee, J. J. Halliday et al., Osteopontin-CD44 signaling in the glioma perivascular niche enhances cancer stem cell phenotypes and promotes aggressive tumor growth, Cell Stem Cell, vol.14, pp.357-369, 2014.

J. Overgaard, J. G. Eriksen, M. Nordsmark, J. Alsner, and M. R. Horsman, Danish H and Neck Cancer Study G. Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: results from the DAHANCA 5 randomised double-blind placebocontrolled trial, Lancet Oncol, vol.6, pp.757-764, 2005.

M. G. Mcnamara, S. Sahebjam, and W. P. Mason, Emerging biomarkers in glioblastoma, Cancers (Basel), vol.5, pp.1103-1119, 2013.

C. W. Brennan, R. G. Verhaak, A. Mckenna, B. Campos, H. Noushmehr et al., The somatic genomic landscape of glioblastoma, Cell, vol.155, pp.462-477, 2013.

C. A. Schneider, W. S. Rasband, and K. W. Eliceiri, NIH Image to ImageJ: 25 years of image analysis, Nature methods, vol.9, pp.671-675, 2012.

N. A. Franken, H. M. Rodermond, J. Stap, J. Haveman, and C. Van-bree, Clonogenic assay of cells in vitro, Nat Protoc, vol.1, pp.2315-2319, 2006.